9-Me-BC Capsules
9-Me-BC Capsules USA — Capsules
Methylated Beta-Carboline Alkaloid
9-Me-BC (9-methyl-beta-carboline) is a small methylated beta-carboline alkaloid studied in neurochemical research models. It is supplied in capsule form strictly for laboratory research use.
This product is intended strictly for laboratory research use within the United States. It is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable U.S. federal, state, and local regulations.
9-Me-BC (9-methyl-beta-carboline) is a small methylated beta-carboline alkaloid studied in neurochemical research models. It is supplied in capsule form strictly for laboratory research use.
In scientific literature, 9-Me-BC has been examined in rodent and cell culture systems, with reported endpoints including monoamine oxidase activity, dopaminergic cell populations in mesencephalic culture, and markers of dendritic and synaptic structure in hippocampal tissue. The published record is limited to a small number of preclinical reports.
Third-party tested for purity, ID, quantity.
Coming Soon
The certificate of analysis for this lot is being finalised and will be published here as soon as the lab returns it.
9-Me-BC belongs to the beta-carboline class, a group of tricyclic alkaloids that occur in plant material and in mammalian tissue and that have been investigated for interactions with monoaminergic systems. In the published work on 9-Me-BC specifically, investigators have reported inhibition of monoamine oxidase activity and, in astrocyte culture, changes in the expression of neurotrophic factors. The mechanistic account across these papers remains partial, and no single pathway has been established as definitive.
Research endpoints evaluated in the literature include the appearance of differentiated dopaminergic neurones in primary mesencephalic culture, measures described by the authors as relating to dopaminergic cell stimulation, protection and regeneration alongside inflammatory markers, and, in rodent work, hippocampal dopamine levels together with dendritic and synaptic proliferation measured against behavioural task performance. All of this work is preclinical. No clinical investigation of 9-Me-BC appears in the candidate record.
9-Me-BC entered the research literature through work on beta-carboline alkaloids and dopaminergic cell culture systems. The earliest of the available reports, from 2008, described its effect on the appearance of differentiated dopaminergic neurones in primary mesencephalic culture, and subsequent papers in 2010 and 2012 extended the work into dopaminergic and hippocampal models in rodents. A later report returned to mechanism, examining monoamine oxidase activity and astrocyte expression of neurotrophic factors.
Beyond this sequence, the origin and early development of the compound are not well documented in the available literature. The record consists of a small cluster of preclinical publications from a narrow set of research groups rather than a broad or sustained investigational programme.
Laboratory investigation of 9-Me-BC has centred on dopaminergic cell culture and rodent neurochemistry. Research frameworks have evaluated monoamine oxidase activity, neurotrophic factor expression in astrocytes, the differentiation and survival of dopaminergic neurones in primary mesencephalic culture, inflammatory markers in those same models, and hippocampal dopamine content alongside dendritic and synaptic structural measures. The body of published work is small, and findings have not been extended beyond preclinical systems.
4 of the 5 areas below are addressed directly by a paper cited on this page.
Dopaminergic neurone culture models
Addressed on this page by Hamann 2008, Polanski 2010. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Hamann, J. et al. (2008) — 9-Methyl-beta-carboline up-regulates the appearance of differentiated dopaminergic neurones in primary mesencephalic culture
- Polanski, W. et al. (2010) — The exceptional properties of 9-methyl-beta-carboline: stimulation, protection and regeneration of dopaminergic neurons coupled with anti-inflammatory effects
Monoamine oxidase activity studies
Addressed on this page by Keller 2020. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Keller, S. et al. (2020) — 9-Methyl-β-carboline inhibits monoamine oxidase activity and stimulates the expression of neurotrophic factors by astrocytes
Neurotrophic factor expression in astrocytes
Addressed on this page by Keller 2020. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Keller, S. et al. (2020) — 9-Methyl-β-carboline inhibits monoamine oxidase activity and stimulates the expression of neurotrophic factors by astrocytes
Hippocampal dopamine and synaptic structure research
Addressed on this page by Gruss 2012, Polanski 2010, Hamann 2008. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Gruss, M. et al. (2012) — 9-Methyl-β-carboline-induced cognitive enhancement is associated with elevated hippocampal dopamine levels and dendritic and synaptic proliferation
- Polanski, W. et al. (2010) — The exceptional properties of 9-methyl-beta-carboline: stimulation, protection and regeneration of dopaminergic neurons coupled with anti-inflammatory effects
- Hamann, J. et al. (2008) — 9-Methyl-beta-carboline up-regulates the appearance of differentiated dopaminergic neurones in primary mesencephalic culture
Neuroinflammation marker models
No paper cited on this page reports on neuroinflammation or marker. This heading marks where 9-Me-BC Capsules is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
The references section of this page cites 4 primary papers published between 2008 and 2020 — a limited but non-trivial record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
9-Me-BC Capsules is frequently listed as a peptide by suppliers in this market. It is not one. The structure published on this page is the compound's actual chemistry, and research on it should be read against its own class rather than against peptide literature.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for 9-Me-BC Capsules, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
9-Me-BC Capsules is commonly described online in connection with faster healing from injury and improved recovery. In the research literature the same compound is filed under dopaminergic neurone culture models, monoamine oxidase activity studies and neurotrophic factor expression in astrocytes.
The 4 papers cited on this page, published between 2008 and 2020 describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Every lot of 9-Me-BC Capsules is independently assayed before it is released, and the certificate for the lot shipped is published rather than summarised. Where a certificate for a current lot is not yet posted, the lot has not yet been released against it.
Researchers who buy 9-Me-BC Capsules in the United States through Eppix Labs receive a batch-labelled vial whose certificate is published against that lot code, so the material can be matched to its analysis rather than to a generic specification.
- Storage
- Cool, dry, away from direct light
- Humidity
- Keep sealed; capsule shells are hygroscopic
- Reconstitution
- Not applicable — supplied pre-measured
- Format
- Oral capsule
9-Me-BC Capsules is supplied in capsule form, which removes the reconstitution step entirely: there is no vehicle to add, no reconstitution volume to record and no post-reconstitution stability window to track. What that leaves a laboratory to control is storage — capsule shells draw moisture from the air, so the container should be kept sealed and dry rather than decanted into an open vessel.
Because the material is already at its labelled quantity per capsule, batch verification carries more weight in this format than it does for powder: there is no point at which the researcher independently confirms mass by weighing. The measured content published for each lot is the figure that answers that question.
- 1 × sealed capsule bottle (10mg per capsule / Single Bottle - Pack of 60), batch-labelled
- Batch documentation for the lot shipped, once its certificate is published
- Discreet outer packaging with no product names on the exterior
- FedEx, tracked, typically 1–3 business days domestically
- Laboratory consumables of any kind
- Dosing, administration or protocol guidance of any kind
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each capsule contains the labeled quantity of 9-Me-BC. Independent third-party analysis verifies purity, identity, and net content per batch.
The container holds only the capsules. Any laboratory materials required for extraction, preparation, or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
9-Methyl-β-carboline-induced cognitive enhancement is associated with elevated hippocampal dopamine levels and dendritic and synaptic proliferation
PubMedThe exceptional properties of 9-methyl-beta-carboline: stimulation, protection and regeneration of dopaminergic neurons coupled with anti-inflammatory effects
PubMed9-Methyl-β-carboline inhibits monoamine oxidase activity and stimulates the expression of neurotrophic factors by astrocytes
PubMed9-Methyl-beta-carboline up-regulates the appearance of differentiated dopaminergic neurones in primary mesencephalic culture
PubMedRelated
You May Also Like
Fisetin-Derived Research Compound CMS-121 is a synthetic small molecule derived from the plant flavonoid fisetin, produced for laboratory research use only. It is supplied in capsule form for controlled experimental work and is not intended for any other application.
$29.99
Uncharacterised Research Compound Compound-7P is supplied as capsules for laboratory research use. The designation "Compound-7P" is a non-systematic label and does not correspond to a single identified chemical entity in the published chemical or pharmacological literature. No PubChem record matches the name, and no molecular formula, sequence or structural profile was supplied with it.
$49.99
Redox-Active Flavin Analogue 5-Deazaflavin is a synthetic analogue of the flavin ring system in which the nitrogen at position 5 of the isoalloxazine core is replaced by carbon. The parent heterocycle (C11H7N3O2, MW 213.19) and its substituted derivatives are produced for laboratory research and are handled within controlled experimental environments.
$59.99
Phenothiazinium Redox Dye Methylene blue is a synthetic phenothiazinium salt and redox-active dye with the molecular formula C16H18ClN3S. It is supplied here in capsule form for laboratory research use within controlled experimental settings.
$29.99